Skip to content

The summer calm is grinding to a halt as members of Congress have returned to D.C. for what is sure to be a busy legislative sprint that could potentially impact all sectors of the biotech industry.

Read More

Vaccine patent waiver breaks faith with American companies, stifles innovation NCBIO is extremely disappointed that the Biden administration has chosen to support waiving critical intellectual property protections for U.S. COVID-19 vaccines. This decision, known as a TRIPS waiver, breaks faith with American innovators, punishes the ingenuity of our life sciences industry and will delay the…

Read More